Cambridge Investment Research Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-61,667	Closed	-$73K	–	3250
2022 Q3	$73K	Buy	61,667 +10,565	+21%	+$16.5K	﹤0.01%	2906
2022 Q2	$92K	Buy	51,102 +9,562	+23%	+$14.1K	﹤0.01%	2881
2022 Q1	$84K	Sell	41,540 -7,350	-15%	-$14.4K	﹤0.01%	3039
2021 Q4	$132K	Sell	48,890 -18,085	-27%	-$66.9K	﹤0.01%	2990
2021 Q3	$299K	Buy	66,975 +3,185	+5%	+$15.3K	﹤0.01%	2474
2021 Q2	$370K	Buy	63,790 +33,243	+109%	+$195K	﹤0.01%	2306
2021 Q1	$214K	Buy	+30,547	New	+$205K	﹤0.01%	2555
2020 Q2	–	Sell	-11,357	Closed	-$72K	–	2531
2020 Q1	$72K	Buy	+11,357	New	+$91.1K	﹤0.01%	2151

Other funds holding CLVS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Cambridge Investment Research Advisors's CLVS Position: Q4 2022 in Review

Cambridge Investment Research Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 61,667 shares — an estimated $73K sold.

Cambridge Investment Research Advisors first reported a position in CLVS in Q1 2020 and held it in 8 quarters. The position peaked at $370K in Q2 2021. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

Cambridge Investment Research Advisors reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
Cambridge Investment Research Advisors sold 61,667 Clovis Oncology, Inc. shares in Q4 2022, an estimated $73K.
Cambridge Investment Research Advisors first reported a position in Clovis Oncology, Inc. in Q1 2020 and held it in 8 quarters.
Cambridge Investment Research Advisors's Clovis Oncology, Inc. position peaked at $370K in Q2 2021.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.